StayCurrentMD · Standardizing the Evaluation and Management of Necrotizing Enterocolitis in a Level IV NICU
Article1 min read·Published Dec 2022Older

Standardizing the Evaluation and Management of Necrotizing Enterocolitis in a Level IV NICU

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Dec 2022 · 1 min read

In brief

In brief

Quality improvement initiative in a Level IV NICU standardized necrotizing enterocolitis management through evidence-based guidelines and EMR tools. Over 5.5 years, the intervention reduced antibiotic days by 39% and NPO days by 33% without increasing mortality, surgery rates, or antifungal use.

Written by the GCMD Library team from the article.

Objectives: Necrotizing enterocolitis (NEC) is a severe intestinal inflammatory disease and a leading cause of morbidity and mortality in NICUs. Management of NEC is variable because of the lack of evidence-based recommendations. It is widely accepted that standardization of patient care leads to improved outcomes. This quality improvement project aimed to decrease variation in the evaluation and management of NEC in a Level IV NICU.

Methods: A multidisciplinary team investigated institutional variation in NEC management and developed a standardized guideline and electronic medical record tools to assist in evaluation and management. Retrospective baseline data were collected for 2 years previously and prospectively for 3.5 years after interventions. Outcomes included the ratio of observed-to-expected days of antibiotics and nil per os (NPO) on the basis of the novel guidelines and the percentage of cases treated with piperacillin/tazobactam. Balancing measures were death, surgery, and antifungal use.

Results: Over 5.5 years, there were 124 evaluations for NEC. Special cause variation was noted in the observed-to-expected antibiotic and NPO days ratios, decreasing from 1.94 to 1.18 and 1.69 to 1.14, respectively. Piperacillin/tazobactam utilization increased from 30% to 91%. There were no increases in antifungal use, surgery, or death.

Conclusions: Variation in evaluation and management of NEC decreased after initiation of a guideline and supporting electronic medical record tools, with fewer antibiotic and NPO days without an increase in morbidity or mortality. A quality improvement approach can benefit patients and decrease variability, even in diseases with limited evidence-based standards.

DOI: 10.1542/peds.2022-056616

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →